Device Trial Radar · NCT04421378
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
74
Actual
Start
Jun 8, 2020
Primary completion
Jul 3, 2023
Study completion Jul 3, 2023
Sponsor
- Lead sponsor
- Karyopharm Therapeutics IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM). This study will be conducted in 2 phases: a Phase 1a dose finding study followed by Phase 1b (dose expansion) and a Phase 2 randomized efficacy exploration study and will independently evaluate 3 different combination regimens in 3 treatment arms in patients with nGBM (Arms A and B) or with rGBM (Arm C). * Arm A: evaluating the combination of selinexor with radiation therapy (S-RT) in nGBM participants with uMGMT * Arm B: evaluating the combination of selinexor with radiation therapy and temozolomide (TMZ) (S-TRT) in nGBM participants with methylated-O6-methylguanine-DNA-methyltransferase (mMGMT) * Arm C: evaluating the combination of selinexor with lomustine (or carmustine, if lomustine is not available) (S-L/C) in rGBM participants regardless of MGMT status * Arm D: evaluating the combination of selinexor with bevacizumab in rGBM participants regardless of MGMT status * Arm E: evaluating the combination of selinexor with tumor treating fields (TTField) in rGBM participants regardless of MGMT status
Conditions
- Glioblastoma Multiforme
Interventions
SelinexorDrug
Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
Temozolomide (TMZ)Drug
Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
Lomustine (CCNU)Drug
Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
Standard Fractionated Radiation therapy (RT)Radiation
Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
BevacizumabDrug
Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
TTFieldDevice
Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
CarmustineDrug
Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a and 1b: Maximum Tolerated Dose of SelinexorTime frame: At Cycle 1 (up to 42 days)
- Phase 1a and 1b: Recommended Phase 2 Dose (RP2D) of SelinexorTime frame: From Cycle 1 Day 1 up to 14 days after last dose (up to 15.41 months) (Each Cycle length = up to 42 days)
- Phase 1a and 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) With Grade Greater Than or Equal to (>=) 3, Serious TEAEs and Who Discontinued Treatment Due to TEAEsTime frame: From first dose of study treatment up to 30 days post last dose (Up to 16.41 months)
2 more outcomes with a free account
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center)
Los Angeles, California
University of California
San Francisco, California
15 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.